Scope of the Study
Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently reported adverse events in patients receiving chemotherapy. If nausea and vomiting become severe, dehydration, metabolic disturbances, malnutrition or aspiration pneumonia may occur. Treatments that prevent or reduce CINV are therefore an integrated part of the supportive care of cancer patients. According to the Cancer Research UK, cancer was caused almost 9.6 million deaths worldwide in 2018.
The market study is being classified by Type (CINV and PONV), by Application (Hospitals, Ambulatory Surgical Centers and Diagnostic Centers) and major geographies with country level break-up.
Merck & Co. (United States), Eisai (Japan), Kyowa Hakko Kirin Co. Ltd. (Japan), Helsinn Holding (Switzerland), Mundipharma International (United Kingdom), Qilu Pharma (China), Teva Pharmaceutical Industries (Israel), Novartis (Switzerland), Heron Therapeutics (United States), Roche Holding AG (Switzerland) and Mylan (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Chemotherapy-Induced Nausea and Vomiting (CINV) market throughout the predicted period.
Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Chemotherapy-Induced Nausea and Vomiting (CINV) market by Type, Application and Region.
On the basis of geography, the market of Chemotherapy-Induced Nausea and Vomiting (CINV) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
If we see Market by , the sub-segment i.e. will boost the Chemotherapy-Induced Nausea and Vomiting (CINV) market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.Market Drivers
- Increase in adoption of chemotherapeutic drugs
- Rise in the Incidence of Cancer Cases
- Growing Healthcare Expenditure and Accelerating Economic Growth
Market Trend
- The Development and Launch of Novel Drug Delivery Methods for CINV Drugs
- High Demand for Combination Therapy and Increasing Preference for Pressure Point Therapy
Restraints
Opportunities
- Growth in Number of Patients Undergoing Chemotherapy Drugs Treatment Across the World
- Increasing Pharmaceutical R&D Spending
Challenges
- Stringent Regulations and High Treatment Cost of Chemotherapy-Induced Nausea and Vomiting (CINV)
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase